论文部分内容阅读
目的:研究血竭对溃疡性结肠炎大鼠模型IL-4、IL-8和IL-10水平的影响,探讨血竭对溃疡性结肠炎的免疫调节作用。方法:将SD大鼠随机分为正常对照组、模型组,模型组用TNBS制备溃疡性结肠炎模型后随机分为模型对照组、柳氮磺胺吡啶对照组、血竭小剂量组、血竭中剂量组和血竭大剂量组,3d后给予相应药物治疗,连续10天。观察黏膜损伤诊断指数(CMDI)变化并测定各组大鼠血清IL-4、IL-8、IL-10水平。结果:治疗后模型对照组大鼠CMDI水平较正常对照组显著升高(P<0.001),血竭各剂量组均可明显降低大鼠CMDI水平(P<0.01或P<0.005)。与模型对照组比较,血竭各剂量组IL-4水平明显升高(P<0.01或P<0.001);IL-8水平无明显变化(P>0.05);血竭小剂量组和中剂量组IL-10水平明显降低(P<0.005或P<0.001)。与SASP对照组比较,血竭小剂量组各项指标无显著性差异(P>0.05)。结论:血竭通过调节IL-4、IL-10等细胞因子水平而调控炎症水平,可能是该药治疗溃疡性结肠炎的机制之一。
Objective: To study the effects of dragon’s blood on the levels of IL-4, IL-8 and IL-10 in rat models of ulcerative colitis, and to explore the immunomodulatory effects of dragon’s blood on ulcerative colitis. METHODS: Sprague-Dawley rats were randomly divided into normal control group and model group. The model group was randomly divided into model control group, sulfasalazine control group, low dose of blood-exposed group, and dragon’s blood in the model of ulcerative colitis prepared with TNBS. In the dose group and the high-dose dragon’s blood group, the corresponding drug treatment was given 3 days later for 10 consecutive days. The change of CMDI was observed and the serum levels of IL-4, IL-8 and IL-10 were determined in each group. Results: After treatment, the level of CMDI in the model control group was significantly higher than that in the normal control group (P<0.001), and the CMDI levels in the rats were significantly decreased in each group (P<0.01 or P<0.005). Compared with the model control group, IL-4 levels were significantly increased in each dose group (P<0.01 or P<0.001); there was no significant change in IL-8 levels (P>0.05); low and medium doses of Dragon’s Blood IL-10 levels decreased significantly (P<0.005 or P<0.001). Compared with the SASP control group, there was no significant difference in each index of the low dose group (P>0.05). Conclusion: Dragon’s Blood regulates the level of inflammation by regulating the levels of IL-4, IL-10 and other cytokines, which may be one of the mechanisms of the drug treatment of ulcerative colitis.